QIAGEN N.V. (QGEN) Form 6-K — Aug 6, 2026
QIAGEN reported second-quarter 2026 net sales of $535.0 million, essentially flat with $533.5 million a year earlier, while net income rose 7% to $103.4 million and diluted EPS grew 14% to $0.50 from $0.44. The Q2 operating income margin expanded to 24.7% from 22.8% as restructuring-driven efficiency gains more than offset higher Parse-related costs plus tariff and currency headwinds. Growth was concentrated in sample technologies, up 9%, helped by the December 2025 Parse Biosciences acquisition, while consumables rose 2% and instrument sales fell 10%. Diagnostic solutions slipped 1% as QIAstat-Dx respiratory demand softened and QuantiFERON latent TB sales declined on a sharp drop in U.S.
Key figures
- Eps
- 0.5
- Revenue
- 535040000
- Net Income
- 103401000
- Total Debt
- 1643622000
- Revenue Yoy
- 0% (Q2 2026 vs Q2 2025); +1% for six months ended June 30, 2026
- Total Assets
- 5889202000
- Cash Position
- 768500000
- Dividend total usd
- 72309000
- Gross margin q2 2026
- 63.6%
- Six month diluted eps
- 0.82
- Dividend per share usd
- 0.35
- Six month net sales usd
- 1027360000
- Operating margin q2 2026
- 24.7%
- Remaining 2027 notes usd
- 26000000
- Six month net income usd
- 171444000
- Capital repayment 2026 usd
- 496700000
- Effective tax rate q2 2026
- 21.7%
- Software asset impairment usd
- 15218000
- Genoox acquisition net cash usd
- 66600000
- Operating cash flow 1h 2026 usd
- 301300000
- Convertible notes 2031 principal usd
- 500000000
- Convertible notes 2032 principal usd
- 750000000
- Restructuring remaining 2026 cost usd
- 18000000
- Restructuring estimated total cost usd
- 75000000
- Max milestone payments through 2027 usd
- 69900000
- Parse acquisition cash consideration usd
- 231000000
- Shares outstanding post synthetic repurchase
- 206800000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.